IOVANCE BIOTHERAPEUTICS INC (IOVA)
Sector: Health Care
2025 Annual Meeting Analysis
IOVANCE BIOTHERAPEUTICS INC · Meeting: June 10, 2025
Directors FOR
1
Directors AGAINST
6
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Dr. Dukes has served as Chairman since August 2016, meaning his tenure fully overlaps the 3-year underperformance period; IOVA's 3-year return of -46.3% trails the company-disclosed peer group median by 73.7 percentage points (threshold: 20pp for negative absolute TSR), and the 5-year check does not provide relief as the 5-year gap of -55.3pp also exceeds the 20pp threshold, confirming sustained underperformance rather than a transient dip.
Dr. Countouriotis has served since June 2019, fully overlapping the underperformance period; IOVA's 3-year return trails the peer group median by 73.7pp (threshold: 20pp), and the 5-year gap of -55.3pp also exceeds the threshold confirming sustained underperformance; additionally, the proxy discloses she missed one or more board meetings in 2024 while attending all committee meetings, raising an attendance concern.
Mr. Maynard has served since February 2015, fully overlapping the underperformance period; IOVA's 3-year return trails the peer group median by 73.7pp (threshold: 20pp for negative absolute TSR), and the 5-year gap of -55.3pp also exceeds the threshold, confirming sustained multi-year underperformance with no 5-year mitigant available.
Mr. Rothbaum has served since June 2016, fully overlapping the underperformance period; IOVA's 3-year return trails the peer group median by 73.7pp (threshold: 20pp for negative absolute TSR), and the 5-year gap of -55.3pp also exceeds the threshold, confirming sustained underperformance; his status as the largest shareholder is noted as context but does not override the TSR trigger under the policy.
Dr. Vogt joined the board in 2024 but has served as an executive officer of the company since 2016 and became Interim CEO in June 2021, meaning his operational oversight substantially overlaps the underperformance period; as an executive director he is subject to the same TSR trigger as all other directors, independent of the Say on Pay vote; the 3-year peer gap of -73.7pp and 5-year peer gap of -55.3pp both exceed the 20pp threshold with no 5-year mitigant.
Dr. Weiser has served since March 2018, fully overlapping the underperformance period; IOVA's 3-year return trails the peer group median by 73.7pp (threshold: 20pp for negative absolute TSR), and the 5-year gap of -55.3pp also exceeds the threshold, confirming sustained underperformance with no 5-year mitigant available.
For Analysis
Ms. Yarno joined the board in June 2023, fewer than 24 months before the meeting date, qualifying her for the new-director exemption under the policy; she is therefore exempt from the TSR underperformance trigger, no overboarding concern is triggered (three public board seats), and no other policy flags apply.
Six of seven directors receive an AGAINST vote due to sustained, severe TSR underperformance: IOVA's 3-year return of -46.3% trails the company-disclosed peer group median by 73.7 percentage points, far exceeding the 20pp trigger threshold applicable to companies with negative absolute TSR, and the 5-year gap of -55.3pp also exceeds the threshold, eliminating any mitigant. Only Wendy Yarno, who joined in June 2023 and qualifies for the 24-month new-director exemption, receives a FOR vote.
Say on Pay
✗ AGAINSTCEO
Frederick G. Vogt, Ph.D., J.D.
Total Comp
$10,953,193
Prior Support
N/A
The CEO received total compensation of $10,953,193 in 2024, which is heavily weighted toward equity awards — a positive structural feature — but the pay-for-performance alignment check fails: IOVA's stock has fallen 46.3% over three years while the XBI (SPDR S&P Biotech ETF) rose 70%, a gap of 116 percentage points, and IOVA trails its own company-disclosed peer group median by 73.7 percentage points over the same period, far exceeding the 20pp threshold for companies with negative absolute TSR. Above-benchmark incentive pay awarded while shareholders experienced this degree of value destruction represents a fundamental misalignment between executive outcomes and shareholder outcomes, warranting a vote against the pay program.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$2,671,488
Non-Audit Fees
$0
In fiscal year 2024, Ernst & Young LLP charged $2,671,488 in audit fees and zero in non-audit fees, resulting in a non-audit ratio of 0%, well below the 50% threshold; EY is a Big 4 firm appropriate for a $1.4B market cap company; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire under policy, and no material restatements are noted.
Overall Assessment
The 2025 Iovance Biotherapeutics annual meeting presents a deeply troubled governance picture: six of seven directors receive AGAINST votes due to IOVA's stock falling 46% over three years while the XBI rose 70% and the company's own peer group median rose 27%, reflecting sustained and severe shareholder value destruction; the Say on Pay vote also receives an AGAINST determination because above-benchmark executive incentive pay was awarded against this backdrop, failing the pay-for-performance alignment test. Only the auditor ratification of Ernst & Young LLP, which charged no non-audit fees in 2024, receives a FOR vote.
Compensation Peer Group
16 companies disclosed in 2025 proxy filing